Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.

ABSTRACT:

Background

The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively studied.

Methods

We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was

SUBMITTER: Moran LV 

PROVIDER: S-EPMC6543546 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature